The ADA Knockout Jurkat Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal population derived from the Jurkat human T lymphoblastoid cell line, featuring targeted disruption of the ADA gene. This model serves as a versatile tool for investigating purine metabolism and T cell signaling pathways.
Jurkat cells are an extensively characterized human T lymphoblastoid cell line derived from an acute T cell leukemia patient, widely employed as a model for T cell receptor signaling, leukemogenesis, and HIV infection studies.
ADA encodes adenosine deaminase, a critical enzyme that irreversibly deaminates adenosine and 2′-deoxyadenosine into inosine and 2′-deoxyinosine, respectively, thereby controlling intracellular and extracellular adenosine levels. In T cells, ADA activity is modulated by T cell receptor signaling, IL-2 stimulation, and NF-??B transcriptional regulation, and it physically interacts with CD26/DPP4 on the cell surface. Downstream of ADA, altered adenosine concentrations impact adenosine receptor (ADORA1, ADORA2A, ADORA2B, ADORA3) signaling cascades, which regulate cAMP/PKA pathways and expression of purine salvage enzymes such as purine nucleoside phosphorylase (PNP). Disruption of ADA function thus perturbs these interconnected signaling networks, leading to aberrant T cell responses.
By disrupting ADA in Jurkat T lymphoblastoid cells, this polyclonal model recapitulates the metabolic and signaling defects underlying adenosine deaminase deficiency, a cause of severe combined immunodeficiency (SCID). The resulting accumulation of adenosine and deoxyadenosine can be exploited to study lymphocytotoxic mechanisms, impaired T cell development, and the immunosuppressive effects of adenosine in the tumor microenvironment, particularly relevant to chronic lymphocytic leukemia.
This ADA knockout Jurkat polyclonal cell population is applicable in diverse experimental contexts, including the dissection of adenosine-mediated T cell activation and suppression, high-throughput screening of adenosine receptor modulators, and preclinical evaluation of enzyme replacement or gene therapy strategies for ADA-SCID. Researchers can monitor ADA enzymatic activity by HPLC, assess downstream cAMP accumulation, perform Western blotting for pathway components such as PKA and phosphorylated substrates, and conduct flow cytometric analysis of CD26 expression and T cell activation markers. Functional assays may include proliferation measurements under adenosine or deoxyadenosine challenge and sensitivity profiling to adenosine receptor agonists and antagonists. RNA-seq and other transcriptomic approaches can further reveal global gene expression changes attributable to adenosine signaling perturbation. For custom assay development or technical support, please contact Ascent Research.
